Who are the analysts and what are their opinions on the efficacy of AstraZeneca's current and future drugs?
What has caused AstraZeneca to make changes to its board?
Why is this a significant setback for AztraZeneca?
How did these changes impact investors' perception of the company?
What future pharmaceutical risks do they anticipate from Crestor?
What is the relationship between Iressa and Tarceva?